New Antifungal as a Potential Cause of Severe Thrombocytopenia: Pancreatitis Due to ACE Inhibitor: Recurrent Hepatitis Due to Cetirizine: Long-Term Cardiovascular Risks Associated with Protease Inhibitors: Pure Red Cell Aplasia and Epoetin Therapy: Pure Red Cell Aplasia Redux: Interferon Therapy: Excellent Drug Reaction Reviews
Restricted accessOtherFirst published online December, 2004
New Antifungal as a Potential Cause of Severe Thrombocytopenia: Pancreatitis Due to ACE Inhibitor: Recurrent Hepatitis Due to Cetirizine: Long-Term Cardiovascular Risks Associated with Protease Inhibitors: Pure Red Cell Aplasia and Epoetin Therapy: Pure Red Cell Aplasia Redux: Interferon Therapy: Excellent Drug Reaction Reviews
The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), to discuss methods of prevention, and to promote reporting of ADRs to the FDA's medWatch program (800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.
In 2004, ISMP is celebrating the 10th anniversary of its incorporation as a nonprofit organization. The Institute represents more than 20 years of experience in helping health care practitioners keep patients safe and continues to lead efforts to improve the medication use process.
Get full access to this article
View all access options for this article.
References
1.
LynchJ., Wong-BeringerA.Caspofungin: a potential cause of reversible severe thrombocytopenia. Pharmacotherapy.2004; 24: 1408–1411.
2.
KanbayM., KorkmazM., VilmazU.Acute pancreatitis due to ramipril therapy. Postgrad Med J.2004; 80(998): 617–618.
3.
PompiliM., BassoM., GriecoA.Recurrent acute hepatitis associated with use of cetirizine. Ann Pharmacother.2004; 38(11): 1844–1847.
4.
KannelW.B., GiodanoM.Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia. Am J Cardiol.2004; 94(7): 901–906.
5.
BennettC.L., LuminariS., NissensonA.R.Pure red-cell aplasia and epoein therapy. N Eng J Med.2004; 351(14): 1403–1408.
6.
TrontellA.Expecting the unexpected: drug safety, pharmacovigilance, and the prepared mind. N Eng J Med.2004; 351(14): 1385–1387.
7.
ArcasoyM.O., RockeyD.C., HeneghanM.A.Pure red cell aplasia following pegylated interferon alfa treatment [letter]. Am J Med.2004; 117(8): 619–620.
8.
VolcheckG.W.Clinical evaluation and management of drug hypersensitivity. Immunol Allergy Clin North Am.2004; 24(3): 357–371.
9.
McKennaJ.K., LeifermanK.M.Dermatologic drug reactions. Immunol Allergy Clin North Am.2004; 24(3): 399–423.
